Clarity Pharmaceuticals recently announced that its pivotal Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA PET for recurrent prostate cancer has fully consented more than the planned 220 participants ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results